AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37976516 — intervention group
Group type: EXPERIMENTAL
Intervention: Change from PL 1.0 to PL 2.5
Number of subjects: 36
Study 37976516 — intervention group
Group type: EXPERIMENTAL
Intervention: Strata shunt at performance level (PL) 0.5
Number of subjects: 36
Study 37976563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 91
Study 37976563 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD education (with or without CBT-I)
Number of subjects: 91
Study 37976633 — intervention group
Group type: EXPERIMENTAL
Intervention: pembrolizumab 200 mg Q3W intravenously for up to 35 cycles
Number of subjects: 187
Study 37976633 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy (treatment of physician's choice per local/country guidelines)
Number of subjects: 187
Study 37976654 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise (HOME)
Number of subjects: 38
Study 37976654 — intervention group
Group type: COMPARATOR
Intervention: Supervised group exercise (GROUP)
Number of subjects: 38
Study 37977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized anxiety at baseline
Number of subjects: 1353
Study 37977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening of generalized anxiety over time
Number of subjects: 1353
Study 37977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement of generalized anxiety over time
Number of subjects: 1353
Study 37977094 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening of cardiac anxiety over time
Number of subjects: 1353
Study 37977105 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment for HR+/HER2- mBC in women aged <40
Number of subjects: 14897
Study 37977105 — intervention group
Group type: COMPARATOR
Intervention: First-line treatment for HR+/HER2- mBC in women aged 40-69
Number of subjects: 14897
Study 37977105 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment for TN mBC in women aged <40
Number of subjects: 14897
Study 37977105 — intervention group
Group type: COMPARATOR
Intervention: First-line treatment for TN mBC in women aged 40-69
Number of subjects: 14897
Study 37977105 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line treatment for HER2+ mBC in women aged <40
Number of subjects: 14897
Study 37977105 — intervention group
Group type: COMPARATOR
Intervention: First-line treatment for HER2+ mBC in women aged 40-69
Number of subjects: 14897
Study 37977159 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 417
Study 37977159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 417
Study 37977159 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 417
Study 37977178 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence to antiretroviral therapy (ARV)
Number of subjects: 147
Study 37977178 — intervention group
Group type: COMPARATOR
Intervention: Sociodemographic, clinical, and psychosocial factors
Number of subjects: 147
Study 37977207 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated service delivery (DSD) eligibility assessment using WHO criteria
Number of subjects: 761
Study 37977207 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal HIV viral load (VL) monitoring
Number of subjects: 761
Study 37977207 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of predictors of virologic failure (VF)
Number of subjects: 761
Study 37977257 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice architecture intervention (banner of daily school meal menu, waterproof tablecloths, posters on healthy eating habits, playful names displays, new containers for fruits, colored footprints) for one month
Number of subjects: 974
Study 37977257 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 974
Study 37977259 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical SYNTAX score
Number of subjects: 0
Study 37977307 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia (NA)
Number of subjects: 4353
Study 37977307 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 4353
Study 37977307 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia with peripheral block (NAP)
Number of subjects: 4353
Study 37977324 — intervention group
Group type: EXPERIMENTAL
Intervention: reslizumab
Number of subjects: 141
Study 37977324 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 141
Study 37977324 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 141
Study 37977335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortico-spinal stimulation (real tDCS) for five days/week for two weeks (T1)
Number of subjects: 31
Study 37977335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortico-spinal stimulation (real tDCS) for five days/week for two weeks (T4)
Number of subjects: 31
Study 37977335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortico-spinal stimulation (real tDCS)
Number of subjects: 31
Study 37977335 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo tDCS)
Number of subjects: 31
Study 37977486 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care (SC) plus gain-framed messaging (GFM)
Number of subjects: 188
Study 37977486 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SC)
Number of subjects: 188
Study 37977486 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on smoking-related biomarkers
Number of subjects: 188
Study 37977486 — intervention group
Group type: COMPARATOR
Intervention: No feedback control
Number of subjects: 188
Study 37977713 — intervention group
Group type: COMPARATOR
Intervention: Lower dose (1.3 × 10^14 vg/kg)
Number of subjects: 26
Study 37977713 — intervention group
Group type: COMPARATOR
Intervention: Higher dose (1.3 × 10^15 vg/kg)
Number of subjects: 26
Study 37977713 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 37977860 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital platform (METHIS) combined with a training programme for clinicians
Number of subjects: 0
Study 37977865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control with norepinephrine infusion targeting intraoperative MAP ≥85 mm Hg
Number of subjects: 80
Study 37977865 — intervention group
Group type: COMPARATOR
Intervention: Routine blood pressure management
Number of subjects: 80
Study 37977865 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight blood pressure control
Number of subjects: 80
Study 37977903 — intervention group
Group type: EXPERIMENTAL
Intervention: Serplulimab plus chemotherapy (etoposide and carboplatin) for four to six cycles, followed by maintenance therapy with serplulimab for up to 2 years.
Number of subjects: 36
Study 37977942 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine (200 μg total toxoid)
Number of subjects: 1317
Study 37977942 — intervention group
Group type: EXPERIMENTAL
Intervention: C difficile vaccine
Number of subjects: 1317
Study 37977942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1317
Study 37978159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (25 mg/kg loading dose then 10 mg/kg/6 h for 5 days)
Number of subjects: 29
Study 37978159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (dose level 1)
Number of subjects: 29
Study 37978159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (dose level 2)
Number of subjects: 29
Study 37978159 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen
Number of subjects: 29
Study 37978197 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus high-dose trastuzumab (6 mg/kg weekly)
Number of subjects: 39
Study 37978266 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual quantification of volumes of 7 lesions and their spatial location
Number of subjects: 29
Study 37978266 — intervention group
Group type: COMPARATOR
Intervention: Automatic 4-class segmentation (without transfer learning)
Number of subjects: 29
Study 37978266 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer learning strategies applied to automatic 4-class segmentation
Number of subjects: 29
Study 37978266 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentations based on transfer learning
Number of subjects: 29
Study 37978284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tovorafenib (420 mg)
Number of subjects: 77
Study 37978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy (rosuvastatin 10 mg plus ezetimibe)
Number of subjects: 3780
Study 37978309 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin (rosuvastatin 20 mg) monotherapy
Number of subjects: 3780
Study 37978309 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin with ezetimibe combination therapy
Number of subjects: 3780
Study 37978378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA) used as primary graft material (≥ 50% by volume) with augmentation up to 50%
Number of subjects: 86
Study 37978378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular bone allograft (CBA)
Number of subjects: 86
Study 37978433 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation strategies including kick-off event, on-site practice facilitation, and interaction with physician expert consultants.
Number of subjects: 102
Study 37978433 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote practice facilitation and web-based tools.
Number of subjects: 102
Study 37978433 — intervention group
Group type: EXPERIMENTAL
Intervention: Contextual factors influencing quality improvement efforts.
Number of subjects: 102
Study 37978433 — intervention group
Group type: EXPERIMENTAL
Intervention: Initiative fatigue among clinicians and practice staff.
Number of subjects: 102
Study 37978433 — intervention group
Group type: EXPERIMENTAL
Intervention: External support for building capacity for quality improvement.
Number of subjects: 102
Study 37978452 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing
Number of subjects: 33000
Study 37978452 — intervention group
Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 33000
Study 37978474 — intervention group
Group type: EXPERIMENTAL
Intervention: Injecting autologous platelet-rich fibrin (i-PRF)
Number of subjects: 21
Study 37978474 — intervention group
Group type: COMPARATOR
Intervention: Control side (no i-PRF injection)
Number of subjects: 21
Study 37978487 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine xenograft with platelet-rich fibrin (PRF) membrane
Number of subjects: 14
Study 37978487 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study 37978488 — intervention group
Group type: EXPERIMENTAL
Intervention: 38% SDF with 5% NaF varnish
Number of subjects: 220
Study 37978488 — intervention group
Group type: COMPARATOR
Intervention: 38% SDF alone
Number of subjects: 220
Study 37978492 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with A1ATD (n=19)
Number of subjects: 463
Study 37978492 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 1-3 groups
Number of subjects: 463
Study 37978492 — intervention group
Group type: COMPARATOR
Intervention: EwAL group (n=61)
Number of subjects: 463
Study 37978492 — intervention group
Group type: EXPERIMENTAL
Intervention: GOLD 3 subjects
Number of subjects: 463
Study 37978528 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies to develop stakeholder interrelationships (35% in Preparation phase, 31% in Implementation phase)
Number of subjects: 287
Study 37978528 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies in the use iterative and evaluative approaches cluster (24% in Preparation phase, 18% in Implementation phase)
Number of subjects: 287
Study 37978528 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategies in the provide interactive assistance, use financial approaches, and support staff clusters
Number of subjects: 287
Study 37978528 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical assistance, support for clinicians, and financial approaches
Number of subjects: 287
Study 37978576 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention (CBI)
Number of subjects: 30
Study 37978576 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention (HBI)
Number of subjects: 30
Study 37978577 — intervention group
Group type: EXPERIMENTAL
Intervention: eCAU plus the stepped-care program (DWM and PM+)
Number of subjects: 210
Study 37978577 — intervention group
Group type: COMPARATOR
Intervention: eCAU
Number of subjects: 210
Study 37978951 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus, 5 mg/m² orally
Number of subjects: 65
Study 37979048 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS and ABR in group 1 (BIND-M score 1-4)
Number of subjects: 56
Study 37979048 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (neonatal hyperbilirubinemia only)
Number of subjects: 56
Study 37979048 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy neonates)
Number of subjects: 56
Study 37979133 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAB regimen (prednisone 40 mg/m2 days 1-5, vinblastine 6 mg/m2 day 1, doxorubicin 40 mg/m2 day 1, bendamustine 120 mg/m2 day 1) every 21 days for 6 cycles
Number of subjects: 89
Study 37979133 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAB regimen
Number of subjects: 89
Study 37979218 — intervention group
Group type: EXPERIMENTAL
Intervention: d-cycloserine augmentation with group exposure therapy
Number of subjects: 152
Study 37979218 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 152
Study 37979594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose short-course oral primaquine (7 mg/kg over 7 days)
Number of subjects: 495
Study 37979594 — intervention group
Group type: COMPARATOR
Intervention: Standard care (single dose oral primaquine of 0.25 mg/kg)
Number of subjects: 495
Study 37979594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose short-course oral primaquine
Number of subjects: 495
Study 37979594 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 495
Study 37979594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 495
Study 37979595 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 518
Study 37979595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study 37979718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitolisant (up to 20 mg/d)
Number of subjects: 512
Study 37979718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 512
Study 37979717 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose heparin
Number of subjects: 727
Study 37979717 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic heparin
Number of subjects: 727
Study 37979717 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of 90-day symptoms
Number of subjects: 727
Study 37979959 — intervention group
Group type: EXPERIMENTAL
Intervention: Avacopan
Number of subjects: 330
Study 37979959 — intervention group
Group type: COMPARATOR
Intervention: Prednisone taper
Number of subjects: 330
Study 37980367 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide plus CC-115 (5 mg twice a day)
Number of subjects: 41
Study 37980467 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01 malaria vaccine
Number of subjects: 63
Study 37980472 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent condom negotiation with partners
Number of subjects: 500
Study 37980472 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent binge drinking in the past month (n=177)
Number of subjects: 500
Study 37980484 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated community-based intervention package including video and audio information on safe motherhood, birth preparedness card, training for community volunteers and health extension workers, and improved maternity waiting home services.
Number of subjects: 727
Study 37980484 — intervention group
Group type: COMPARATOR
Intervention: Routine services only (Control group).
Number of subjects: 727
Study 37980490 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention for urinary incontinence (SMI-UI) including a mobile application, handbook, and professional support.
Number of subjects: 0
Study 37980490 — intervention group
Group type: COMPARATOR
Intervention: Attention control group receiving a single dietetic education information package.
Number of subjects: 0
Study 37980494 — intervention group
Group type: EXPERIMENTAL
Intervention: STOP intervention (practice-embedded nurse care manager, brief advice from PCP, up to 6 sessions of telephone health coaching)
Number of subjects: 0
Study 37980494 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) (primary care treatment as usual, printed overdose prevention educational materials, educational video on cancer screening)
Number of subjects: 0
Study 37980511 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder-sparing therapies (BST)
Number of subjects: 572
Study 37980511 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy
Number of subjects: 572
Study 37980687 — intervention group
Group type: EXPERIMENTAL
Intervention: ABM training (N=16)
Number of subjects: 32
Study 37980687 — intervention group
Group type: COMPARATOR
Intervention: Control (N=16)
Number of subjects: 32
Study 37980767 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-clinical (PC) group
Number of subjects: 1133
Study 37980767 — intervention group
Group type: COMPARATOR
Intervention: Clinically diagnosed (CD) group
Number of subjects: 1133
Study 37980801 — intervention group
Group type: EXPERIMENTAL
Intervention: Written Exposure Therapy
Number of subjects: 95
Study 37980801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Number of subjects: 95
Study 37980801 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonresponders)
Number of subjects: 95
Study 37980875 — intervention group
Group type: EXPERIMENTAL
Intervention: Group iterative multiple model estimation (GIMME) applied to examine the relationships between various emotions and suicidal ideation (SI) among individuals with borderline personality disorder who underwent Dialectical Behavior Therapy.
Number of subjects: 0
Study 37980911 — intervention group
Group type: EXPERIMENTAL
Intervention: BPaLM
Number of subjects: 552
Study 37980911 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 552
Study 37980921 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic and local therapy group (n=53)
Number of subjects: 104
Study 37980921 — intervention group
Group type: COMPARATOR
Intervention: Systemic therapy only group (n=51)
Number of subjects: 104
Study 37980921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 37980922 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront endoscopic necrosectomy
Number of subjects: 70
Study 37980922 — intervention group
Group type: COMPARATOR
Intervention: Step-up treatment
Number of subjects: 70
Study 37980924 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (weight-adjusted twice-daily)
Number of subjects: 512
Study 37980924 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC, no systemic anticoagulation)
Number of subjects: 512
Study 37981049 — intervention group
Group type: EXPERIMENTAL
Intervention: SY-009 (1.0-4.0 mg)
Number of subjects: 50
Study 37981049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 37981090 — intervention group
Group type: COMPARATOR
Intervention: First-line osimertinib
Number of subjects: 891
Study 37981090 — intervention group
Group type: COMPARATOR
Intervention: Later-line osimertinib
Number of subjects: 891
Study 37981473 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination
Number of subjects: 26
Study 37981564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 0
Study 37981564 — intervention group
Group type: COMPARATOR
Intervention: CART therapies
Number of subjects: 0
Study 37981564 — intervention group
Group type: COMPARATOR
Intervention: Anti-CD20 antibody-based regimens
Number of subjects: 0
Study 37981596 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg
Number of subjects: 40
Study 37981596 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 12 mg
Number of subjects: 40
Study 37981596 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib (both doses)
Number of subjects: 40
Study 37981596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37981662 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral model-guided nutritional counseling
Number of subjects: 263
Study 37981665 — intervention group
Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP)
Number of subjects: 54
Study 37981665 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin gel applied weekly for four weeks after SRP
Number of subjects: 54
Study 37981665 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (healthy gingiva)
Number of subjects: 54
Study 37981893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 123
Study 37981893 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid impact
Number of subjects: 123
Study 37981892 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) and 'on-demand' plerixafor
Number of subjects: 301
Study 37981892 — intervention group
Group type: EXPERIMENTAL
Intervention: Plerixafor
Number of subjects: 301
Study 37982152 — intervention group
Group type: EXPERIMENTAL
Intervention: ACURATE neo2 valve implantation
Number of subjects: 250
Study 37982276 — intervention group
Group type: EXPERIMENTAL
Intervention: sLOX-1 above the median
Number of subjects: 327
Study 37982276 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein quartile 4 (≥4.0 mg/L)
Number of subjects: 327
Study 37982381 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anticoagulation with LMWH (13.2%) or DOAC (7.1%) for patients with higher VTE risk
Number of subjects: 1878
Study 37982381 — intervention group
Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 1878